Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SASHA: Single Fraction Interstitial Breast Brachytherapy
NCT07654257Phase 2Recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Oct 2026
- Primary completion
- Oct 2036
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Virginia Commonwealth University. Primary endpoint: Toxicity of 1-day APBI at 5 years. Started Oct 2026; status: recruiting.
Beyond the preview
Go deeper on NCT07654257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654257.